MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
MIRA Pharmaceuticals reported positive 21-day preclinical results showing oral MIRA-55 significantly reduced chronic inflammatory pain (p < 0.001 vs vehicle) with efficacy comparable to celecoxib (Celebrex) at higher doses. Pain relief was sustained across the three-week study without tolerance, swelling was reduced, and no adverse clinical signs were observed across all doses and both sexes.
Key figures
- Drug Name
- MIRA-55
- Phase Of Trial
- Preclinical (21-day proof-of-concept, CFA model)
- Comparator
- celecoxib (Celebrex)
- Dea status
- not a controlled substance
- Study subjects
- 72 male and female rats
- Study duration days
- 21
- Ind submission target
- Q1 2027
- Statistical significance
- p < 0.001 vs vehicle
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.